Skip to main content

Table 1 Patient characteristics

From: CXCL13 predicts disease activity in early rheumatoid arthritis and could be an indicator of the therapeutic `window of opportunity'

 

Baseline

6 months

DAS28CRP

5.7 (5.1-6.5)

2.1 (1.8-2.8)

Swollen joint count (0-28)

10 (7.0-17)

0 (0-0)

Tender joint count (0-28)

12 (7.0-18)

0 (0-1.3)

Swollen joint count (0-40)

13 (9.0-22)

0 (0-0)

Tender joint count (0-40)

17 (11-26)

0 (0-3.0)

VAS doctor global (0-100 mm)

56 (41-73)

2.0 (0-10)

CRP (mg/ml)

15 (7.0-42)

7.0 (7.0-7.0)

SDAI (0.7-82)

37 (29-47)

3.1 (0.86-7.0)

IgM-RF (% positive)

70.7%

-

Anti-CCP (% positive)

62.7%

-

TSS (% positive)

17.3%

-

  1. Relevant disease markers at baseline and following 6 months of treatment. Data are expressed as median with interquartile range (IQR). Anti-CCP: anti-citrullinated protein antibody; CRP: C-reactive protein; DAS28CRP: disease activity in 28 joints, four variables, C-reactive protein based; IgM-RF: IgM rheumatic factor; SDAI: simple disease activity index; TSS: total Sharp score; VAS: visual analog scale.
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us